A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E Mutation

Clinical trial NCT05641493 · UNKNOWN

Trial details

NCT number: NCT05641493
Sponsor: Shanghai Henlius Biotech
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Non Small Cell Lung Cancer

Start date: 2023-02-28
Primary completion: 2025-03-04
Enrollment: 49

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.